Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.58 |
| ▸ | CES1 | P23141 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.58 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 4/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | APAF1 | O14727 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132795 | 1.00 | TGM2 (0.58) | TGM2CES1ALDH1A1CHRM1ALDH3A1 | |
| SCHEMBL1337353 | 0.82 | CA12 (0.57) | ALDH1A1CA12MAPTPOLBHPGD | |
| SCHEMBL18955151 | 0.81 | CA1 (0.71) | CA12 | |
| SCHEMBL18954691 | 0.80 | TGM2 (0.68) | TGM2CES1ALDH1A1CHRM1ALDH3A1 | |
| SCHEMBL5426500 | 0.79 | TGM2 (0.52) | TGM2CES1ALDH1A1CHRM1ALDH3A1 | |
| SCHEMBL18974754 | 0.78 | TGM2 (0.61) | TGM2CES1ALDH1A1CHRM1ALDH3A1 | |
| SCHEMBL5430327 | 0.78 | CHRM1 (0.63) | TGM2CES1ALDH1A1CHRM1ALDH3A1 | |
| SCHEMBL18954909 | 0.78 | ALDH1A1 (0.71) | TGM2CES1ALDH1A1CHRM1ALDH3A1 | |
| SCHEMBL15928248 | 0.78 | TGM2 (0.75) | TGM2CES1ALDH1A1CHRM1ALDH3A1 | |
| SCHEMBL4596020 | 0.78 | TGM2 (0.61) | TGM2CES1ALDH1A1CHRM1ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234938-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-07-27 | — | — | US | disclosed |
| CN-115485271-A | Novel compounds as inhibitors of poly (ADP-ribose) polymerase (PARP) | 理森制药股份公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2017099695-A1 | N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | ISTANBUL UNIVERSITESI REKTORLUGU (TR) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017099695-A1 | N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | ISTANBUL UNIVERSITESI REKTORLUGU (TR) | 2017-06-15 | — | — | WO | disclosed |
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| EP-1877378-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-01-16 | — | — | EP | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| WO-2006113864-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | TGM2 4700/4885CES1 4183/4885ALDH1A1 1136/4885 |
| US-20230234938-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | TGM2 605/4885CES1 498/4885ALDH1A1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.